Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28045452 | 0.80 | — | — | |
| SCHEMBL27257119 | 0.75 | GAA (0.33) | ALOX15 | |
| SCHEMBL28120282 | 0.74 | MEN1 (0.32) | MEN1ALDH1A1MAPTPKMALOX15 | |
| SCHEMBL10767394 | 0.68 | — | — | |
| SCHEMBL4890557 | 0.67 | HTR6 (0.34) | — | |
| SCHEMBL27729342 | 0.67 | HTR2C (0.33) | MEN1ALDH1A1MAPTPKMALOX15 | |
| SCHEMBL27895099 | 0.65 | HTR2C (0.33) | MEN1ALDH1A1MAPTPKMALOX15 | |
| SCHEMBL6489205 | 0.65 | — | — | |
| SCHEMBL28281585 | 0.64 | MEN1 (0.31) | MEN1ALDH1A1MAPTPKMALOX15 | |
| SCHEMBL27266578 | 0.64 | MEN1 (0.34) | MEN1ALDH1A1MAPTPKMALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1026588-C | 1-alkyl substituted benzimidazole derivatives, process for preparing same and pharmaceutical composition containing same | JANSSEN PHARMACEUTICA NV (BE) | 1994-11-16 | — | — | CN | claimed |
| CN-88101286-A | 1-alkyl substituted benzimidazole derivatives, process for preparing same and pharmaceutical composition containing same | — | 1988-09-28 | — | — | CN | claimed |
| CN-116947852-A | Synthesis method of zimetapam intermediate | 南通常佑药业科技有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-107428744-A | Novel heterocyclic compounds and its application in medicine and cosmetics | 盖尔德马研究及发展公司 | 2017-12-01 | — | — | CN | disclosed |
| CN-106432232-A | Synthesis method of 1-piperidin-4-yl-1,3-dihydro-imidazol[4, 5-b]pyridine-2-one | 苏州汉德创宏生化科技有限公司 | 2017-02-22 | — | — | CN | disclosed |
| CN-106061969-A | TRPA1 modulators | 阿尔戈么迪克斯有限公司 | 2016-10-26 | — | — | CN | disclosed |
| US-20050256167-A1 | Preparation and use of imidazole derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-11-17 | — | — | US | disclosed |
| EP-1163239-A1 | MODIFIED AMINO-ACID AMIDES AS CGRP ANTAGONISTS | Boehringer Ingelheim Pharma KG (DE) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000055154-A1 | MODIFIED AMINO-ACID AMIDES AS CGRP ANTAGONISTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-09-21 | — | — | WO | disclosed |
| CN-1026588-C | 1-alkyl substituted benzimidazole derivatives, process for preparing same and pharmaceutical composition containing same | JANSSEN PHARMACEUTICA NV (BE) | 1994-11-16 | — | — | CN | disclosed |
| CN-1018614-B | Process for preparing antihistaminic compositions containing N-heterocyclyl-4-piperidinamines | JANSSEN PHARMACEUTICA NV (BE) | 1992-10-14 | — | — | CN | disclosed |
| CN-88101286-A | 1-alkyl substituted benzimidazole derivatives, process for preparing same and pharmaceutical composition containing same | — | 1988-09-28 | — | — | CN | disclosed |
| CN-87100563-A | The anti-histamine compositions that contains N-heterocyclic radical-4-piperidinamines | — | 1987-08-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256167-A1 | Preparation and use of imidazole derivatives for treatment of obesity | GPR119, GIPR, PGC | MEN1 1397/4885ALDH1A1 2202/4885MAPT 3231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.